Medicinal Leech Genome Assembly — Anticoagulant Gene Catalog
First chromosome-level genome for Hirudo medicinalis with 15 anticoagulation genes
Why this matters for hirudotherapy
Investigational / Research Priority
Investigación en ciencia básica. Esta revisión cubre hallazgos genómicos con implicaciones traslacionales indirectas para el descubrimiento futuro de fármacos.
La necesidad de un genoma de referencia
Despite centuries of use in medicine and decades of molecular research, Hirudo medicinalis lacked a high-quality reference genome until 2020. Previous genetic studies relied on fragmented transcriptome data or targeted gene sequencing. Kvist et al. addressed this gap with the first chromosome-level genome assembly, providing the foundation for systematic gene discovery.[R1]
Estadísticas del ensamblaje
176.96
Megabase pairs (Mbp)
19,929
Scaffolds
14
Chromosome-scale scaffolds
Catálogo de genes anticoagulantes
The study’s primary contribution was a comprehensive catalog of genes encoding anticoagulation and antihemostatic proteins. The researchers annotated:
15 anticoagulation factors
Including multiple hirudin variants, Factor Xa inhibitors (lefaxin, antistasin), and thrombin-binding proteins. Several gene families showed evidence of lineage-specific duplication, suggesting evolutionary refinement of the anticoagulant repertoire.
17 antihemostatic proteins
Including platelet aggregation inhibitors (calin, saratin), fibrinolytic enzymes (destabilase), and matrix-degrading enzymes (hyaluronidase). These collectively disable every major step in the hemostatic cascade.
Descubrimientos novedosos
Beyond confirming known genes, the genome assembly revealed several novel findings:
| Discovery | Significance |
|---|---|
| Lefaxin gene family | Novel Factor Xa inhibitors distinct from antistasin; potential drug leads for next-generation anticoagulants |
| Hirudin gene expansion | Multiple hirudin paralogs suggesting functional diversification — different variants may target different thrombin exosites |
| CRISP proteins | Cysteine-rich secretory proteins with unknown function; potential ion channel modulators based on homology |
| M12/M13 proteases | Metalloprotease families potentially involved in tissue penetration and extracellular matrix remodeling |
Implicaciones para el descubrimiento de fármacos
The genome assembly enables a paradigm shift in leech-derived drug discovery. Rather than the historical approach of isolating one compound at a time through biochemical purification, researchers can now use the genome as a roadmap to identify, clone, and express candidate therapeutic proteins recombinantly.
Bivalirudin
Hirudin-inspired direct thrombin inhibitor. FDA-approved. Peak revenue $596M/year. Now generic.
Desirudin
Recombinant hirudin analog for DVT prophylaxis. FDA-approved. Demonstrates the path from leech compound to drug.
Lefaxin (preclinical)
Novel Factor Xa inhibitor identified through genomics. Represents the next generation of leech-derived drug candidates.
Complementary proteomics
References
- [R1]
A Chromosome-Level Genome Assembly for the Medicinal Leech and Identification of Anticoagulant Genes
Primary source. First chromosome-level genome assembly of Hirudo medicinalis.
- [R2]
Integrated Proteomics and Transcriptomics of Hirudo medicinalis Salivary Gland Secretion
Liu et al. proteomics study that complements the genomic catalog.
- [R3]
Comparative Transcriptomics of Three Hirudo Species
Babenko et al. extending the genomic perspective across Hirudo species.
Recursos relacionados
Added to ASH library: February 27, 2026 | Site last updated: March 14, 2026